FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1881545913> ?p ?o ?g. }

• W1881545913 endingPage "2230" @default.
• W1881545913 startingPage "2222" @default.
• W1881545913 abstract "To evaluate the use of biological agents for the treatment of psoriasis and to explore country-specific differences within six Central and Eastern European (CEE) countries, namely Bulgaria, Croatia, the Czech Republic, Hungary, Poland and Romania.A literature overview on the epidemiology and disease burden of psoriasis in CEE was conducted. The number of patients treated with biologics was obtained from patient registries, ministries of health, national professional societies and health insurance funds. Biological treatment rates were estimated by two different methods: (i) as a proportion of all psoriasis patients of a country (assuming a common prevalence of psoriasis 2%) and (ii) per 100,000 population. Moreover, we provide a detailed comparison of drug coverage policies and guidelines regulating the treatment with biologics in psoriasis.On average 0.25% of all psoriasis patients, or five psoriasis patients out of 100,000 inhabitants are treated with biologics embedding a 14.6-fold difference between the six countries. Bulgaria, Croatia and Poland lag behind the other three countries in the use of biologics. The significant differences among CEE countries cannot be explained by variations in prices of biologics, cost-effectiveness or budget impact of biologics. It seems that the time since coverage decision, the fewer number of covered biologics, the more restrictive criteria to be eligible for covered treatment in terms of baseline Psoriasis Area and Severity Index and Dermatology Life Quality Index scores, and the maximum duration of treatment allowed are responsible for the majority of the differences.There exists a disconnect between the European psoriasis treatment guidelines and the various CEE country-specific biologic coverage eligibilities. The cost of biologic therapy for psoriasis is not solely and directly responsible for the different use rates amongst the CEE countries. Psoriasis may not be perceived by all payers as a serious disease that can be successfully treated in a cost-effective manner." @default.
• W1881545913 created "2016-06-24" @default.
• W1881545913 creator A5005121565 @default.
• W1881545913 creator A5013020612 @default.
• W1881545913 creator A5017418790 @default.
• W1881545913 creator A5024021740 @default.
• W1881545913 creator A5034446187 @default.
• W1881545913 creator A5042185810 @default.
• W1881545913 creator A5056333439 @default.
• W1881545913 creator A5059098836 @default.
• W1881545913 creator A5064557440 @default.
• W1881545913 creator A5065073085 @default.
• W1881545913 creator A5068277876 @default.
• W1881545913 creator A5086557976 @default.
• W1881545913 creator A5090377619 @default.
• W1881545913 date "2015-09-14" @default.
• W1881545913 modified "2023-09-30" @default.
• W1881545913 title "Use of biologics for psoriasis in Central and Eastern European countries" @default.
• W1881545913 cites W1527901496 @default.
• W1881545913 cites W1877047792 @default.
• W1881545913 cites W1939757787 @default.
• W1881545913 cites W1971934381 @default.
• W1881545913 cites W1973791399 @default.
• W1881545913 cites W1981336058 @default.
• W1881545913 cites W2008984680 @default.
• W1881545913 cites W2021018799 @default.
• W1881545913 cites W2029612923 @default.
• W1881545913 cites W2034992158 @default.
• W1881545913 cites W2041613754 @default.
• W1881545913 cites W2056733295 @default.
• W1881545913 cites W2057699446 @default.
• W1881545913 cites W2060836363 @default.
• W1881545913 cites W2067706450 @default.
• W1881545913 cites W2069350424 @default.
• W1881545913 cites W2071065705 @default.
• W1881545913 cites W2072119926 @default.
• W1881545913 cites W2073608069 @default.
• W1881545913 cites W2084666330 @default.
• W1881545913 cites W2096272522 @default.
• W1881545913 cites W2122897116 @default.
• W1881545913 cites W2128554753 @default.
• W1881545913 cites W2134206785 @default.
• W1881545913 cites W2151444904 @default.
• W1881545913 cites W2152262899 @default.
• W1881545913 cites W2165657093 @default.
• W1881545913 cites W2169804509 @default.
• W1881545913 doi "https://doi.org/10.1111/jdv.13222" @default.
• W1881545913 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26370506" @default.
• W1881545913 hasPublicationYear "2015" @default.
• W1881545913 type Work @default.
• W1881545913 sameAs 1881545913 @default.
• W1881545913 citedByCount "37" @default.
• W1881545913 countsByYear W18815459132015 @default.
• W1881545913 countsByYear W18815459132016 @default.
• W1881545913 countsByYear W18815459132017 @default.
• W1881545913 countsByYear W18815459132018 @default.
• W1881545913 countsByYear W18815459132019 @default.
• W1881545913 countsByYear W18815459132020 @default.
• W1881545913 countsByYear W18815459132021 @default.
• W1881545913 countsByYear W18815459132022 @default.
• W1881545913 countsByYear W18815459132023 @default.
• W1881545913 crossrefType "journal-article" @default.
• W1881545913 hasAuthorship W1881545913A5005121565 @default.
• W1881545913 hasAuthorship W1881545913A5013020612 @default.
• W1881545913 hasAuthorship W1881545913A5017418790 @default.
• W1881545913 hasAuthorship W1881545913A5024021740 @default.
• W1881545913 hasAuthorship W1881545913A5034446187 @default.
• W1881545913 hasAuthorship W1881545913A5042185810 @default.
• W1881545913 hasAuthorship W1881545913A5056333439 @default.
• W1881545913 hasAuthorship W1881545913A5059098836 @default.
• W1881545913 hasAuthorship W1881545913A5064557440 @default.
• W1881545913 hasAuthorship W1881545913A5065073085 @default.
• W1881545913 hasAuthorship W1881545913A5068277876 @default.
• W1881545913 hasAuthorship W1881545913A5086557976 @default.
• W1881545913 hasAuthorship W1881545913A5090377619 @default.
• W1881545913 hasBestOaLocation W18815459132 @default.
• W1881545913 hasConcept C144024400 @default.
• W1881545913 hasConcept C149923435 @default.
• W1881545913 hasConcept C159110408 @default.
• W1881545913 hasConcept C16005928 @default.
• W1881545913 hasConcept C2779951463 @default.
• W1881545913 hasConcept C2780564577 @default.
• W1881545913 hasConcept C2908647359 @default.
• W1881545913 hasConcept C71924100 @default.
• W1881545913 hasConcept C99454951 @default.
• W1881545913 hasConceptScore W1881545913C144024400 @default.
• W1881545913 hasConceptScore W1881545913C149923435 @default.
• W1881545913 hasConceptScore W1881545913C159110408 @default.
• W1881545913 hasConceptScore W1881545913C16005928 @default.
• W1881545913 hasConceptScore W1881545913C2779951463 @default.
• W1881545913 hasConceptScore W1881545913C2780564577 @default.
• W1881545913 hasConceptScore W1881545913C2908647359 @default.
• W1881545913 hasConceptScore W1881545913C71924100 @default.
• W1881545913 hasConceptScore W1881545913C99454951 @default.
• W1881545913 hasIssue "11" @default.
• W1881545913 hasLocation W18815459131 @default.
• W1881545913 hasLocation W18815459132 @default.
• W1881545913 hasLocation W18815459133 @default.

• next